PATHOPHYSIOLOGY OF COVID-19 IN DIABETIC PATIENTS: CRITICAL REVIEW

Abstract

At the time of writing the global population is facing a life-threatening pandemic, in the form of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the novel coronavirus first reported in Wuhan, China in 2019, and is commonly referred to as coronavirus disease 2019 (COVID-19). Understanding the pathophysiology of this condition is essential to establishing appropriate treatment options. Therefore, a comprehensive review of the literature produced to date is essential. The focus of this review is on the interaction between SARS-2, diabetes and inflammation. Diabetes is itself approaching pandemic proportions, and is associated with a deregulation of the immune system. The information on these components of the COVID-19 pathology will allow a rationale for therapeutics. Seems there is a correlation of diabetic people with COVID-19, therefore, revision of the common features of diabetes inflammation and COVID-19 are summarised in this review. The information of all this review supports the rationale for the formulation of therapeutic approaches.